An 89% complete response rate across 45 patients is a number that almost never appears in relapsed/refractory AL amyloidosis, a disease where the heart and kidneys absorb enough amyloid protein to fail before most treatments take hold. Immix Biopharma disclosed that figure in an 8-K filed September 29, 2026, reporting that 40 of 45 enrolled patients in the NEXICART-2 Phase 2 trial achieved a complete response to NXC-201, its BCMA-targeted CAR-T cell therapy, as assessed by an independent review committee.
The detail that sharpens that headline rate is what happened among the 25 most recently enrolled patients. Twenty-one reached complete response outright, and the other four tested MRD-negative in bone marrow. Immix has argued that bone marrow MRD negativity predicts future organ recovery, which matters in AL amyloidosis because organ damage, not just hematologic burden, determines survival. If the MRD-negative patients do convert to organ responses on follow-up, the trial’s functional benefit could broaden beyond the CR count.
NXC-201 carries what Immix describes as a steric optimization and a “digital filter” designed to suppress non-specific T-cell activation, a feature the company has emphasized to distinguish its construct from earlier BCMA CAR-T programs. The earlier NEXICART-1 study, conducted outside the United States, generated the proof-of-concept data published in the Journal of Clinical Oncology. NEXICART-2 is the U.S. Phase 2 study expanding on that foundation. AL amyloidosis affects roughly 16.7 people per million in the United States annually, a rate growing at nearly 8% per year since 2019, making it a rare but expanding target.
The clinical question NEXICART-2 now needs to answer is durability. A CR rate means little in AL amyloidosis if responses are short-lived, because the amyloid already deposited in organs does not clear automatically. The next data disclosure worth tracking is the organ response rate among those four MRD-negative patients who did not yet meet the formal CR threshold, since their trajectory will test whether the hematologic depth of this 89% result translates to the end-organ outcomes that actually change how long patients live.
Source link: https://www.sec.gov/Archives/edgar/data/1873835/000149315226044761/form8-k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
